Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HINT1 | P49773 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28719205 | 0.91 | KDM4E (0.59) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL19146280 | 0.91 | KDM4E (0.59) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL22883498 | 0.91 | KDM4E (0.59) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL24222098 | 0.91 | KDM4E (0.59) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL21376544 | 0.90 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL20782390 | 0.90 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL21637043 | 0.90 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL22034209 | 0.86 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL24166695 | 0.86 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL18521073 | 0.86 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | KDM4E 2160/4885TAS1R3 671/4885TAS1R1 387/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | KDM4E 2160/4885TAS1R3 671/4885TAS1R1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.